Please note that this product was withdrawn from the Community Register of designated orphan medicinal products in November 2016 at the end of the period of market exclusivity.
On 29 December 2000, orphan designation (EU/3/00/010) was granted by the European Commission to Shire Pharmaceutical Development Ltd, United Kingdom, for anagrelide hydrochloride for the treatment of essential thrombocythaemia.
The sponsorship was transferred to Shire Pharmaceuticals Contracts Ltd, United Kingdom, in December 2001.
Anagrelide hydrochloride has been authorised in the EU as Xagrid since 16 November 2004.
More information on Xagrid can be found in the European public assessment report (EPAR) on the Agency's website.
Treatment of essential thrombocythaemia
|Orphan designation status||
|EU designation number||
|Date of designation||
Shire Pharmaceuticals Contracts Ltd
Hampshire International Business Park
Hants RG24 8EP
Telephone: +44 12 56 89 40 00
Telefax: +44 12 56 89 47 08
Documents related to this orphan designation evaluation
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: